BRCA2 and ovarian cancer: In the clinical studies of continuous versus discontinuous dosing schedules in ovarian cancer patients, it was evident that continuous treatment was superior [35], but our pre-clinical studies with Capan-1 (BRCA2 mutant pancreatic carcinoma) cells and xenografts suggested that a short exposure to rucaparib was sufficient to produce durable PARP inhibition and antitumour activity [36].